Yes, Myoclonus Can Occur with Propofol Induction
Myoclonus is a recognized adverse effect of propofol during anesthesia induction, though it occurs less frequently than with etomidate. This phenomenon is well-documented in both FDA labeling and clinical guidelines, and clinicians should be prepared to recognize and manage it when it occurs.
Evidence from FDA Labeling and Guidelines
The FDA-approved propofol label explicitly lists myoclonus as a known side effect, stating that "perioperative myoclonia, rarely including convulsions and opisthotonos, has occurred in association with propofol injectable emulsion administration" 1. This is the highest-quality evidence available, as it represents regulatory acknowledgment of this adverse effect.
Multiple clinical practice guidelines corroborate this finding. The 2013 Critical Care Medicine guidelines specifically identify myoclonus among propofol's "other side effects" alongside hypertriglyceridemia and acute pancreatitis 2. The 2012 multisociety sedation curriculum for gastrointestinal endoscopy notes that clinicians must be "skilled in the recognition of delayed propofol-related adverse events that may arise after recovery from sedation, such as fever, chills, or myalgia that may arise within 48 hours of administration" 3, though myoclonus typically occurs during or immediately after induction rather than as a delayed phenomenon.
Clinical Characteristics and Timing
Propofol-induced myoclonus typically manifests during or shortly after induction, within the first 20 minutes of administration. Case reports and clinical studies demonstrate that these movements can range from brief, mild tremors to more severe myoclonic contractions 4, 5, 6. In one veterinary study examining propofol total intravenous anesthesia, myoclonus occurred in 1.2% of cases, appearing within 20 minutes after induction and primarily involving limb muscles 6.
The movements are characterized as involuntary muscle contractions that:
- Do not cease following additional propofol or opioid boluses
- Are of sufficient severity to interfere with the procedure
- Occur despite adequate depth of anesthesia
- Are distinct from inadequate hypnosis or analgesia 6
Comparison with Etomidate
While propofol can cause myoclonus, etomidate produces this side effect far more frequently. The 2005 emergency medicine clinical policy guidelines provide comparative data: etomidate alone caused myoclonus in 37.9% of patients, while the addition of fentanyl or droperidol reduced this to approximately 11-14% 7. In contrast, propofol's myoclonus incidence appears substantially lower, though exact comparative rates are not well-established in the guidelines.
A 2026 study comparing fospropofol (a propofol prodrug) with etomidate in elderly patients undergoing hip surgery found myoclonus occurred in only 1.7% of the fospropofol group versus 31.7% in the etomidate group (P<0.001) 8. This dramatic difference reinforces that while propofol can cause myoclonus, it does so far less frequently than etomidate.
Management Strategies
When propofol-induced myoclonus occurs, the primary management approach is to reduce or discontinue the propofol infusion and increase alternative agents. A 2023 case report of intraoperative propofol-induced myoclonus demonstrated that the movements did not improve with:
- Deepening anesthesia with additional propofol
- Opioid boluses
- Discontinuation of concurrent lidocaine infusion
However, myoclonus ceased after reducing the propofol infusion rate and increasing ketamine and opioid infusions 5. This suggests a dose-dependent relationship and the importance of recognizing propofol as the causative agent rather than attempting to treat with more propofol.
Clinical Pitfalls and Considerations
The paradoxical nature of propofol-induced myoclonus is a critical pitfall: propofol has well-established anticonvulsant properties, yet in susceptible patients under certain conditions, it can act as a proconvulsant 4. This dual nature means clinicians may initially misattribute the movements to inadequate anesthesia depth and inappropriately increase propofol dosing, potentially worsening the situation.
Additional considerations include:
- Pain on injection occurs in up to 30% of patients and can be minimized by using larger veins or pretreatment with lidocaine 9
- Rapid bolus administration increases the risk of adverse effects, including myoclonus 1
- Pediatric patients may be particularly susceptible, with one case report describing myoclonus in a 1-year-old during induction 4
- Prolonged or severe myoclonus may rarely be accompanied by meningism (neck stiffness, photophobia) that resolves spontaneously 10
Risk Mitigation
To minimize the risk of propofol-induced myoclonus:
- Use slower injection rates rather than rapid boluses
- Allow adequate time (3-5 minutes) between dose adjustments 1
- Consider pretreatment with small doses of opioids, which may reduce excitatory phenomena
- Maintain awareness that myoclonus can occur despite adequate anesthesia depth
- Be prepared to switch to alternative agents if myoclonus develops and persists
The key clinical message is that while propofol-induced myoclonus is uncommon (occurring in approximately 1-2% of cases), it is a recognized phenomenon that requires prompt recognition and management through dose reduction or agent substitution rather than escalation of propofol dosing.